Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03846479 · ClinicalTrials.gov registry record · Phase 2
Itacitinib for Low Risk GVHD
A Phase 2 study, sponsored by John Levine.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT03846479 is a Phase 2 study that has completed, run by John Levine. The registered enrollment target is 70 participants.
The verdict
NCT03846479, a Phase 2 study, has completed, sponsored by John Levine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
Graft-versus-host disease (GVHD) is treated with high doses of systemic steroids which can lead to serious complications. A new blood test can identify patients whose GVHD is most likely to respond to well to treatment (low risk GVHD). This study will test whether patients with low risk GVHD can be successfully treated without steroids. Patients who participate with this study will be treated with itacitinib instead of steroids. Itacitinib is an experimental drug with an excellent safety record and appears to have activity as a GVHD treatment.
Interventions
- DRUG Itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2022-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03846479
The ClinicalTrials.gov registry entry for NCT03846479 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Levine, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Itacitinib is the first listed.
NCT03846479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03846479 about?
NCT03846479 is a clinical study titled "Itacitinib for Low Risk GVHD". Graft-versus-host disease (GVHD) is treated with high doses of systemic steroids which can lead to serious complications. A new blood test can identify patients whose GVHD is most likely to respond to well to treatment (low risk GVHD). This study will test whether patients with low risk GVHD can be ...
What is the current status of trial NCT03846479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2019-03-25. Estimated completion is 2022-05-11.
What interventions are being tested in trial NCT03846479?
The interventions under investigation include: Itacitinib (DRUG).
Who is sponsoring clinical trial NCT03846479?
This trial is sponsored by John Levine, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.